

## EACR 2023 Congress Abstracts

### Contents

#### PROFFERED PAPER PRESENTATIONS ..... 2

Rising Star and Top Abstracts.....	2
Symposium: Interface between the Microbiome and Immune System.....	3
Symposium: Drug Resistance .....	4
Symposium: Mechanism Based Clinical Trial.....	5
Symposium: Challenging Drug Targets .....	7
Joint EACR-SIC Symposium: Spatial Transcriptomics .....	8
Symposium: Cell Adaptation and Competition.....	9
Symposium: Tumour Metabolism and Epigenetic Control ..	10
Joint EACR-AACR Symposium: Computational Biology and AI in Research and Cancer Care .....	11
Symposium: Normal Tissue and the Biology of Early Cancer .....	12
Symposium: Drugging the RAS Pathway.....	13
Symposium: Advanced T-Cell Therapy.....	14
Symposium: Cancer Models.....	15
Symposium: Tumour Ecology and Evolution at Single Cell Level .....	16
Symposium: Tumour Dormancy / Persistence / Senescence 17	
Symposium: Neoantigens & Vaccines .....	19
Symposium: Liquid Biopsies.....	20
Symposium: Chemical Biology .....	21

#### POSTER PRESENTATIONS (Tuesday/Wednesday) ..... 22

Bioinformatics and Computational Biology .....	22
Biomarkers in Tissue and Blood .....	52
Cancer Cell Biology .....	107
Poster in the Spotlight.....	220
Cancer Genomics.....	224
Poster in the Spotlight.....	248
Poster in the Spotlight.....	249
Carcinogenesis .....	252

Drug Resistance .....	264
Poster in the Spotlight.....	268
Epigenetics .....	314
Poster in the Spotlight.....	316
Experimental / Molecular Therapeutics, Pharmacogenomics .....	328
Immunotherapy.....	388
Molecular and Genetic Epidemiology .....	413
Prevention and Early Detection .....	416
Radiobiology / Radiation Oncology .....	420
Poster in the Spotlight.....	431
Signalling Pathways.....	432
Translational Research .....	449
Tumour Biology.....	480
Poster in the Spotlight.....	536
Tumour Evolution and Heterogeneity .....	554
Poster in the Spotlight.....	556
Poster in the Spotlight.....	559
Tumour Immunology .....	570
Poster in the Spotlight.....	580
Poster in the Spotlight.....	582
Poster in the Spotlight.....	593

#### Proffered Papers

10-minute talks awarded for the highest scored abstracts, embedded in the scientific symposia sessions. These presentations are not accompanied by a poster.

#### Posters in the Spotlight

Tuesday 13 June, 17:30- 18:30, Poster and Exhibition Hall  
Wednesday 14 June, 17:15- 18:15, Poster and Exhibition Hall

Dedicated sessions taking place in the spotlight area within the Poster and Exhibition Hall. Poster presenters with high scoring abstracts will give short presentations of up to 10 minutes. Their posters will also be available to view during the Poster Discussion Sessions.

## EACR23-1160

### Resistance Mechanisms to c-MET inhibition in Hepatocellular Carcinoma

R. Qian<sup>1</sup>, W. Cun<sup>1</sup>

<sup>1</sup>State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China

#### Introduction

c-MET has emerged as a promising therapeutic target for hepatocellular carcinoma (HCC), and several clinical trials of c-MET inhibitors for HCC are currently ongoing globally. Capmatinib and tepotinib are two recently approved c-MET selective inhibitors by the FDA in 2020. However, the development of resistance in single-agent therapies is an inevitable challenge in clinical applications, which highlights the need to understand the mechanism of c-MET inhibitors resistance.

#### Material and Methods

A panel of HCC cell lines was treated with increasing concentrations of c-MET inhibitors. To systematically identify the kinase whose inhibition confers resistance to capmatinib in primary sensitive HCC cells, we conducted a CRISPR-Cas9 functional genetic screen. Multiple long-term colony formation assays and western blot were used to study the synergistic effects of the combination of c-MET inhibitors and other potential therapeutic inhibitors.

#### Results and Discussions

We identified that *PTEN* knockout leads to robust resistance to c-MET inhibitors in MHCC97H and HCCLM3 cells. Molecular mechanism studies showed that the level of AKT phosphorylation can serve as a biomarker for the response to c-MET inhibitors. Furthermore, suppression of c-MET in HCC leads to feedback activation of upstream receptor tyrosine kinases ERBB2 and ERBB3, which in turn upregulate the AKT signaling pathway and confer resistance to c-MET inhibitors. Therefore, drugs that inhibit both ERBB2 and ERBB3 can reverse unresponsiveness to c-MET inhibitors in c-MET-resistant HCC cells.

#### Conclusion

Our findings demonstrated the resistance mechanism for c-MET inhibitors in HCC. More importantly, we propose following solutions for HCC cell lines which are resistant to c-MET inhibitors: (i) combination of c-MET inhibitors and AKT inhibitor MK2206; (ii) combination of c-MET inhibitors and ERBB2/ERBB3 inhibitors Afatinib or Dacomitinib.

## EACR23-1164

### Nrf2 role in the BRAFi/MEKi acquired resistance in melanoma

M.A. Cucci<sup>1</sup>, M. Grattarola<sup>1</sup>, C. Monge<sup>2</sup>, A. Roetto<sup>1</sup>, C. Dianzani<sup>2</sup>, S. Pizzimenti<sup>1</sup>

<sup>1</sup>University of Turin, Clinical and Biological Science, Torino, Italy

<sup>2</sup>University of Turin, Scienza e Tecnologia del Farmaco, Torino, Italy

#### Introduction

Melanoma is one of the most aggressive cancers with the poorest prognosis. However, the use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival. Nevertheless, half of

the patients still develop resistance within the first year of therapy. Therefore, understanding the mechanisms of BRAFi/MEKi acquired resistance has become a priority for researchers. In these last few years, scientists have focused on the role of NF-E2-related factor 2 (Nrf2), the master regulator of the cytoprotective and antioxidant response, in acquired chemoresistance. Indeed, its expression and activity are upregulated in various cancer types resistant to several chemotherapeutic drugs. The aim of this study was to evaluate the contribution of Nrf2 in the BRAFi/MEKi acquired resistance in melanoma, as well as the mechanisms of its activity regulation.

#### Material and Methods

Starting from BRAF-mutated murine melanoma cell line D4M, we generated three subclones resistant to BRAFi (dabrafenib, D), MEKi (trametinib, T), and BRAFi/MEKi (double resistance, D+T). Then, we evaluated cell viability (MTT test), anchorage-independent cell growth (Sphere Formation and Soft Agar Assays), apoptosis (Annexin V/PI), Cell invasion (Transwell Boyden chamber), angiogenesis (Tube-Formation assay), intracellular oxidative stress (2'-7'-dichlorodihydrofluorescein diacetate, DCF-DA, assay), glutathione (GSH) levels (Ellman's method), gene expression (western blot, real-time PCR), and gene expression inhibition with specific siRNA.

#### Results and Discussions

After nine months of continuous treatments with D, T or D+T, we obtained the three resistant subclones. Compared with the sensitive clone, the resistant sublines showed higher resistance to D, T, or D+T treatments and an enhanced ability to anchorage-independent cell growth with increased migration and angiogenic capacity. These results allowed us to consider these cell lines good models of resistant melanoma cells toward targeted therapies. These cells showed increased oxidative stress and GSH levels. Nrf2 was upregulated at post-translational levels, with the involvement of deubiquitinase 3 (DUB3). Interestingly, Nrf2 or DUB3 inhibition sensitised cells to targeted therapies.

#### Conclusion

Nrf2 can contribute to the mechanism of targeted resistance in melanoma. A complete understanding of its role can contribute to developing increasingly effective therapies in advanced melanoma.

## EACR23-1171

### Cross-talk between TNBC cells and adipose mesenchymal stem cells contributes to maintaining a hostile acidic microenvironment and increases PDL-1 expression

A. Sarnella<sup>1</sup>, Y. Ferrara<sup>2</sup>, M.G. Caprio<sup>2</sup>, L. Cerchia<sup>3</sup>, G. De Simone<sup>2</sup>, C.T. Supuran<sup>4</sup>, A. Zannetti<sup>2</sup>

<sup>1</sup>Istituto di Biostrutture e Bioimmagini - Consiglio Nazionale delle Ricerche, National Research Council, Napoli, Italy

<sup>2</sup>Institute of Biostructures and Bioimaging-CNR, National Research Council, Napoli, Italy

<sup>3</sup>Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore", National Research Council, Napoli, Italy

<sup>4</sup>Università di Firenze,

Dipartimento NEUROFARBA- Sezione di Scienze Farmace